Drug Approvals

• The US Food and Drug Administration (FDA) approved 22 novel drugs during the first half of 2026, expanding treatment options across various medical specialties. • Key approvals include copper histidinate (formerly CUTX-101) for Menkes disease, supported by two open-label studies involving 129 patients treated with subcutaneous administration for up to 3 years. • The FDA also granted approval for a new treatment targeting mild to moderate Alzheimer's disease (AD) based on phase 3 clinical trial data from both adult and pediatric populations.

• The American Journal of Health-System Pharmacy has outlined the pharmaceutical pipeline for novel drug approvals anticipated between 1Q 2026 and 4Q 2026. • The upcoming pipeline focuses on therapies for rare inherited genetic disorders, immunologic and inflammatory diseases, and advancements in gene therapy and targeted oncology. • This tracking is critical for health-system pharmacists to effectively manage hospital formularies, allocate financial resources, and optimize patient care.

• Regulatory bodies are increasingly integrating real-world evidence (RWE) into the drug approval process to supplement traditional randomized clinical trials. • This shift utilizes real-world data (RWD) sourced from electronic health records, administrative claims databases, disease registries, and digital health tools. • The adoption of RWE allows for a more comprehensive understanding of patient health and healthcare delivery, potentially accelerating decision-making for pharmaceutical companies.

• The FDA approved Icotyde (icotrokinra), developed by Johnson & Johnson Innovative Medicine, on March 17, 2026. • The drug is an interleukin-23 (IL-23) receptor antagonist specifically indicated for patients with moderate-to-severe plaque psoriasis. • This approval provides a new therapeutic option for managing a chronic inflammatory skin condition by targeting specific immune responses.

• FDA announced on April 1, 2026, that new drug approvals last year reached near-record levels, surpassing five-, ten-, and multi-year averages. • This update highlights continued acceleration in innovative therapies reaching US patients, boosting treatment options for various diseases. • Strong approval momentum underscores FDA's commitment to expediting safe, effective drugs amid public health priorities like cancer and rare diseases.